Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA Conference Paper uri icon

Overview

MeSH Major

  • Heart Valve Diseases
  • Quality of Life
  • Surveys and Questionnaires

abstract

  • This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

publication date

  • October 1999

Research

keywords

  • Conference Paper

Identity

Digital Object Identifier (DOI)

  • 10.1097/00000658-199910000-00002

Additional Document Info

start page

  • 466

end page

  • 70; discussion 470-2

volume

  • 230

number

  • 4